Kary Mullis, PhD is President of Altermune, a research company in chemically programmable immunity to cure infectious diseases. He received a Bachelor of Science degree in chemistry from the Georgia Institute of Technology in 1966 and a Ph.D. degree in biochemistry from the University of California, Berkeley, in 1972. That year, Dr. Mullis became a postdoctoral fellow in pediatric cardiology at the University of Kansas Medical School, with emphasis in the areas of angiotensin and pulmonary vascular physiology. In 1977 he began two years of postdoctoral work in pharmaceutical chemistry at the University of California, San Francisco. Dr. Mullis received a Nobel Prize in chemistry in 1993, for his invention of the polymerase chain reaction (PCR). The process, which Dr. Mullis conceptualized in 1983, is a method of amplifying DNA. PCR multiplies a single, microscopic strand of the genetic material billions of times within hours. The process has multiple applications in medicine, genetics, biotechnology, and forensics. His most recent patent application covers a revolutionary approach to instantly mobilize the immune system to neutralize invading pathogens and toxins, leading to the formation of his latest venture, Altermune LLC. Altermune is currently focusing on Influenza A, anthrax and drug resistant Staphylococcus aureus.
No Video AvailableKary Mullis